Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
talnetant · 4 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| talnetant | EXPERIMENTAL | 200mg, 400mg, 600mg) twice a day |
| placebo | PLACEBO_COMPARATOR | placebo |
| risperidone | ACTIVE_COMPARATOR | 3mg twice a day |
| Name | Type | Description |
|---|---|---|
| Talnetant | DRUG | talnetant |
| placebo | OTHER | Placebo Comparator |
| risperidone | OTHER | Active Comparator |
Inclusion criteria: * Subjects must have schizophrenia which is not secondary to another medical condition or substance abuse. * Require inpatient hospitalization. * Woman may enroll only if they are not of child-bearing potential OR are on a protocol-approved birth control method. Exclusion crite...
Talnetant is an investigational small molecule being studied for irritable colon (irritable bowel syndrome) and schizophrenia. It has been evaluated in Phase 2 clinical trials for both conditions, but it is not approved and remains in clinical development.
Talnetant is being developed by GSK plc, traded on the London Stock Exchange under the ticker GSK. The company has sponsored multiple Phase 2 trials of the drug in schizophrenia and irritable bowel syndrome.
Talnetant is in Phase 2 clinical development. All three completed trials were Phase 2 studies, including two in schizophrenia and one in irritable bowel syndrome. The drug is investigational and has not been approved by regulatory authorities.
Talnetant has completed three Phase 2 trials: NCT00049946 in schizophrenia (231 participants), NCT00101985 in irritable bowel syndrome (741 participants), and NCT00103727 in schizophrenia (282 participants). A fourth trial, NCT00300963, also studied talnetant in schizophrenia with 275 participants.
Talnetant is not known by alternative names in the available data. It is a distinct investigational compound developed by GSK plc for gastrointestinal and psychiatric indications.